[{"id":"4bbdcbf6-ccbf-4476-adeb-a48a0a44206f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225363","created_at":"2022-02-05T18:29:53.670Z","updated_at":"2024-07-02T16:35:01.290Z","phase":"Phase 1","brief_title":"Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05225363","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TAG72-CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 05/05/2022","start_date":" 05/05/2022","primary_txt":" Primary completion: 04/05/2026","primary_completion_date":" 04/05/2026","study_txt":" Completion: 04/05/2027","study_completion_date":" 04/05/2027","last_update_posted":"2024-05-23"},{"id":"03e89ab8-dacb-455b-84eb-7a4c304f5cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06338657","created_at":"2024-03-29T14:40:53.948Z","updated_at":"2024-07-02T16:35:02.933Z","phase":"Phase 1","brief_title":"FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer","source_id_and_acronym":"NCT06338657","lead_sponsor":"University of Southern California","biomarkers":" PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15","pipe":"","alterations":" ","tags":["PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nanoencapsulated paclitaxel (FID-007)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-05-17"},{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"d5870014-be37-4a8f-b38f-acf430db9ed2","acronym":"TIBIOP-LMC","url":"https://clinicaltrials.gov/study/NCT04645706","created_at":"2021-01-19T20:39:33.885Z","updated_at":"2024-07-02T16:35:40.883Z","phase":"","brief_title":"Innate T Cells and TKI Discontinuation","source_id_and_acronym":"NCT04645706 - TIBIOP-LMC","lead_sponsor":"Poitiers University Hospital","biomarkers":" CD8 • IFNG • IL2RA • CCR7 • ITGA4 • PRF1 • B3GAT1 • ISG20","pipe":" | ","alterations":" CD8 expression • IFNG expression","tags":["CD8 • IFNG • IL2RA • CCR7 • ITGA4 • PRF1 • B3GAT1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • IFNG expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-08-04"},{"id":"36ca1f5c-c2f6-4841-9b20-252eb2f23150","acronym":"","url":"https://clinicaltrials.gov/study/NCT04987996","created_at":"2021-08-03T18:52:59.526Z","updated_at":"2024-07-02T16:35:46.330Z","phase":"Phase 2","brief_title":"GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients","source_id_and_acronym":"NCT04987996","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" CD8 • IL2RA • CCR7 • CD27 • LGALS3 • FAS • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["CD8 • IL2RA • CCR7 • CD27 • LGALS3 • FAS • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • belapectin (GR-MD-02)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2023-06-06"},{"id":"a007902a-0a7f-41d6-85c9-d3d6c51f4f3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02689453","created_at":"2021-01-18T13:07:06.175Z","updated_at":"2024-07-02T16:36:11.245Z","phase":"Phase 1","brief_title":"Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)","source_id_and_acronym":"NCT02689453","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["CD8 • TNFRSF8 • CCR4 • IL2RA • CD4 • NCAM1 • CCR7 • CD52 • FAS • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/19/2017","start_date":" 01/19/2017","primary_txt":" Primary completion: 06/15/2021","primary_completion_date":" 06/15/2021","study_txt":" Completion: 06/15/2021","study_completion_date":" 06/15/2021","last_update_posted":"2022-04-29"},{"id":"1b165c6f-ea64-459f-b1f5-2f8e3a98fc1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02573259","created_at":"2021-01-17T17:43:00.102Z","updated_at":"2024-07-02T16:36:19.570Z","phase":"Phase 1","brief_title":"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors","source_id_and_acronym":"NCT02573259","lead_sponsor":"Pfizer","biomarkers":" PD-L1 • ALK • CD8 • PD-1 • CCR7","pipe":" | ","alterations":" EGFR mutation • ALK mutation • PD-1 positive","tags":["PD-L1 • ALK • CD8 • PD-1 • CCR7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zumrad (sasanlimab)"],"overall_status":"Completed","enrollment":" Enrollment 147","initiation":"Initiation: 02/10/2016","start_date":" 02/10/2016","primary_txt":" Primary completion: 11/19/2020","primary_completion_date":" 11/19/2020","study_txt":" Completion: 11/19/2020","study_completion_date":" 11/19/2020","last_update_posted":"2021-12-13"},{"id":"9c5e4e1e-d50a-4f40-aa00-425ef29cbd1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00520130","created_at":"2021-01-18T01:52:41.568Z","updated_at":"2024-07-02T16:37:02.230Z","phase":"Phase 2","brief_title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","source_id_and_acronym":"NCT00520130","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4 • CCR7 • IL7","pipe":"","alterations":" ","tags":["CD8 • CD4 • CCR7 • IL7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Campath (alemtuzumab) • sirolimus • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 10/30/2007","start_date":" 10/30/2007","primary_txt":" Primary completion: 10/14/2015","primary_completion_date":" 10/14/2015","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2019-03-05"},{"id":"9de1f7e7-ee3c-4744-8a41-ac93419cdd06","acronym":"","url":"https://clinicaltrials.gov/study/NCT02132182","created_at":"2021-01-18T09:53:26.826Z","updated_at":"2024-07-02T16:37:09.347Z","phase":"","brief_title":"Monocyte Phenotypic and Functional Differences","source_id_and_acronym":"NCT02132182","lead_sponsor":"Duke University","biomarkers":" CCR7 • FCGR2A • CCR2 • FCGR2B","pipe":"","alterations":" ","tags":["CCR7 • FCGR2A • CCR2 • FCGR2B"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 03/23/2017","primary_completion_date":" 03/23/2017","study_txt":" Completion: 03/23/2017","study_completion_date":" 03/23/2017","last_update_posted":"2018-06-29"},{"id":"723d4da3-7e27-4714-91ea-857da90e411e","acronym":"CCR7-CD4-DPL","url":"https://clinicaltrials.gov/study/NCT03280290","created_at":"2021-01-18T16:11:55.192Z","updated_at":"2024-07-02T16:37:18.005Z","phase":"","brief_title":"Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft","source_id_and_acronym":"NCT03280290 - CCR7-CD4-DPL","lead_sponsor":"University Hospital, Lille","biomarkers":" CD4 • CCR7","pipe":"","alterations":" ","tags":["CD4 • CCR7"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/20/2012","start_date":" 03/20/2012","primary_txt":" Primary completion: 04/01/2017","primary_completion_date":" 04/01/2017","study_txt":" Completion: 04/01/2017","study_completion_date":" 04/01/2017","last_update_posted":"2017-09-12"}]